ClinicalTrials.gg
CompletedNCT06034743BaxHTNUpdated Nov 3, 2026Results posted

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A Phase 3 interventional study of Baxdrostat and Placebo in Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca. Completed at 263 sites in 29 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Posted results revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
796
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
3rd of 18
796 · median 197
Started
2023
the only one that year
Phase 3
6 of 18
2 open now
Registered
11th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 11th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).

03

Conditions studied

  • Uncontrolled Hypertension
  • Resistant Hypertension

Browse trials for

Keywords

  • Hypertension
  • Uncontrolled hypertension
  • Resistant hypertension
  • Blood pressure
  • Baxdrostat
  • CIN-107
  • Aldosterone
  • Aldosterone synthase
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants must be ≥ 18 years old
  • Mean sitting systolic blood pressure on automated office blood pressure measurement ≥ 140 mmHg and \< 170 mmHg at Screening
  • Fulfil at least 1 of the following 2 criteria:

    1. uHTN subpopulation: have a stable regimen of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
    2. rHTN subpopulation: have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator
  • Estimated ≥ 45 mL/min/1.73m2 at Screening
  • Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening
  • Randomisation Criterion:
  • Sitting systolic blood pressure on attended automated office blood pressure measurement of ≥ 135 mmHg at the Baseline Visit

Exclusion criteria

Exclusion Criteria:

  • Mean sitting systolic blood pressure on attended automated office blood pressure measurement ≥ 170 mmHg
  • Mean seated diastolic blood pressure on attended automated office blood pressure measurement ≥ 110 mmHg
  • Serum sodium level \< 135 mmol/L at Screening
  • Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation
  • functional heart failure class IV at Screening
  • Persistent atrial fibrillation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
796 participants (actual)

Study arms

  • Experimental
    2 mg baxdrostat

    2 mg baxdrostat administered orally, once daily (QD).

    Drug: Baxdrostat

  • Experimental
    1 mg baxdrostat

    1 mg baxdrostat administered orally, once daily (QD).

    Drug: Baxdrostat

  • Placebo comparator
    Placebo

    Placebo administered orally, once daily (QD).

    Drug: Placebo

Interventions

  • Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: * 1 mg per tablet for 1 mg baxdrostat Arm; * 2 mg per tablet for 2 mg baxdrostat Arm.

    Also known as: CIN-107

  • DrugPlacebo

    Placebo tablet matching baxdrostat, administered orally, once daily (QD).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat

    To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  2. Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat

    To assess the effect of 1 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

Secondary outcomes

  1. Change From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat

    To assess the effect of 2 mg baxdrostat vs placebo on seated systolic blood pressure (SBP) at 8 weeks after randomised withdrawal (RWD). All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 32

  2. Change From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation

    To assess the effect of 2 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  3. Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat

    To assess the effect of 2 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  4. Number of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat

    To assess the effect of 2 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  5. Change From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation

    To assess the effect of 1 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  6. Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat

    To assess the effect of 1 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

  7. Number of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat

    To assess the effect of 1 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.

    Time frame: At Week 12

07

Results

Posted Jul 30, 2026

Participant flow

The study was done from 22 November 2023 to 05 November 2025. Participants were screened and randomised from 269 study sites across 29 countries. A total of 794 participants were randomised and treated in the study.

Double-Blind Treatment Period Weeks 0-12
Participant flow — Double-Blind Treatment Period Weeks 0-12
MilestoneDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboOpen-Label Period Weeks 13-24 Baxdrostat 2mgOpen-Label Period Weeks 13-52 Standard of CareRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboOpen-Label Period Weeks 33-52 Baxdrostat 2mg
Started26426626400000
Completed24523724600000
Not completed19291800000
Open-Label Period Weeks 13-24
Participant flow — Open-Label Period Weeks 13-24
MilestoneDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboOpen-Label Period Weeks 13-24 Baxdrostat 2mgOpen-Label Period Weeks 13-52 Standard of CareRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboOpen-Label Period Weeks 33-52 Baxdrostat 2mg
Started0004830000
Completed0004620000
Not completed000210000
Open-Label Period Weeks 13-52
Participant flow — Open-Label Period Weeks 13-52
MilestoneDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboOpen-Label Period Weeks 13-24 Baxdrostat 2mgOpen-Label Period Weeks 13-52 Standard of CareRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboOpen-Label Period Weeks 33-52 Baxdrostat 2mg
Started0000245000
Completed0000238000
Not completed00007000
Randomised Withdrawal Period Weeks 25-32
Participant flow — Randomised Withdrawal Period Weeks 25-32
MilestoneDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboOpen-Label Period Weeks 13-24 Baxdrostat 2mgOpen-Label Period Weeks 13-52 Standard of CareRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboOpen-Label Period Weeks 33-52 Baxdrostat 2mg
Started00000172850
Completed00000163820
Not completed00000930
Open-Label Period Weeks 33-52
Participant flow — Open-Label Period Weeks 33-52
MilestoneDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboOpen-Label Period Weeks 13-24 Baxdrostat 2mgOpen-Label Period Weeks 13-52 Standard of CareRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboOpen-Label Period Weeks 33-52 Baxdrostat 2mg
Started0000000245
Completed0000000236
Not completed00000009

Outcome measures

SecondaryChange From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat

To assess the effect of 2 mg baxdrostat vs placebo on seated systolic blood pressure (SBP) at 8 weeks after randomised withdrawal (RWD). All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 32
Reported as:
Least squares mean · mmHg
Change From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat
mmHgRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 Placebo
Change From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat-3.7 ± 0.91.4 ± 1.3
Statistical analysis
  • Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg vs Randomised Withdrawal Period Weeks 25-32 Placebo · ANCOVA · p = 0.0016 (Secondary endpoints were tested sequentially. A 0.05 alpha was to be carried forward to subsequent tests if both primary hypotheses were rejected (until a null wasn't rejected), or a 0.025 alpha if only one was rejected.) · Least square mean difference: -5.1 · 95% CI -8.3 to -1.9Analyzed using an ANCOVA model with treatment and HTN (uHTN, rHTN) as factors, and RWD baseline (Week 24) seated SBP value as a covariate.
SecondaryChange From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation

To assess the effect of 2 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation-15.2 ± 1.2-5.4 ± 1.3
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = <0.0001 · Least square mean difference: -9.8 · 95% CI -13.1 to -6.4Analyzed using an ANCOVA model with treatment as a factor, and baseline seated SBP value as a covariate.
SecondaryChange From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat

To assess the effect of 2 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat-6.9 ± 0.6-3.0 ± 0.7
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = <0.0001 · Least square mean difference: -3.9 · 95% CI -5.7 to -2.0Analyzed using an ANCOVA model with treatment and HTN at baseline (uHTN, rHTN) as factors, and baseline seated DBP value as a covariate.
SecondaryNumber of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat

To assess the effect of 2 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat
ParticipantsDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Number of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat10649
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.9 · 95% CI 1.9 to 4.4Analyzed using a logistic regression model with baseline SBP value as a covariate and treatment and HTN category at baseline (uHTN, rHTN) as factors. An odds ratio greater than 1 favors baxdrostat.
SecondaryChange From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation

To assess the effect of 1 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation-14.5 ± 1.2-5.4 ± 1.3
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = <0.0001 · Least square mean difference: -9.1 · 95% CI -12.6 to -5.7Analyzed using an ANCOVA model with treatment as a factor, and baseline seated SBP value as a covariate.
SecondaryChange From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat

To assess the effect of 1 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat-6.3 ± 0.7-3.0 ± 0.7
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = 0.0008 · Least square mean difference: -3.3 · 95% CI -5.2 to -1.4Analyzed using an ANCOVA model with treatment and HTN at baseline (uHTN, rHTN) as factors, and baseline seated DBP value as a covariate.
SecondaryNumber of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat

To assess the effect of 1 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat
ParticipantsDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Number of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat10449
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 2.9 · 95% CI 1.9 to 4.3Analyzed using a logistic regression model with baseline SBP value as a covariate and treatment and HTN category at baseline (uHTN, rHTN) as factors. An odds ratio greater than 1 favors baxdrostat.
PrimaryChange From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat

To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat-15.7 ± 1.0-5.8 ± 1.0
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = <0.0001 (Dual primary endpoints were pre-specified to be tested simultaneously at two-sided alpha of 0.025 each. The first secondary endpoint was to be tested at alpha of 0.05 if both were rejected, or at alpha 0.025 if only one was rejected.) · Least square mean difference: -9.8 · 95% CI -12.6 to -7.0Analysed using an ANCOVA model with treatment and hypertension (HTN) type at baseline (uncontrolled HTN \[uHTN\], resistant HTN \[rHTN\]) as factors, and baseline seated SBP value as a covariate.
PrimaryChange From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat

To assess the effect of 1 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.

Time frame:
At Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat
mmHgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Placebo
Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat-14.5 ± 1.0-5.8 ± 1.0
Statistical analysis
  • Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg vs Double-Blind Treatment Period Weeks 0-12 Placebo · ANCOVA · p = <0.0001 (Dual primary endpoints were pre-specified to be tested simultaneously at two-sided alpha of 0.025 each. The first secondary endpoint was to be tested at alpha of 0.05 if both were rejected, or at alpha 0.025 if only one was rejected.) · Least square mean difference: -8.7 · 95% CI -11.5 to -5.8Analysed using an ANCOVA model with treatment and HTN type at baseline (uHTN, rHTN) as factors, and baseline seated SBP value as a covariate.

Adverse events

Collected over From first dose of study drug to the end of study at Week 54. Note that the study was analyzed in five analysis periods: Double-Blind Treatment Weeks 0-12 (both cohorts), RWD Weeks 25-32 (C1 only), Weeks 0-24 (both cohorts; including the 2-week safety follow-up (SFU) period till Week 26 for C2), Weeks 0-52 (C1 only; including the 2-week SFU period till Week 54 for C1) and Weeks 13-52 (both cohorts; including the 2-week SFU period till Week 26 for C2 and Week 54 for C1).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg0/264 (0%)5/264 (1.9%)49/264 (18.6%)
Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg0/266 (0%)9/266 (3.4%)64/266 (24.1%)
Double-Blind Treatment Period Weeks 0-12 Placebo1/264 (0.4%)7/264 (2.7%)39/264 (14.8%)
Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg0/172 (0%)4/172 (2.3%)27/172 (15.7%)
Randomised Withdrawal Period Weeks 25-32 Placebo0/85 (0%)0/85 (0%)9/85 (10.6%)
Weeks 0-24 Analysis Period Baxdrostat0/481 (0%)33/481 (6.9%)145/481 (30.1%)
Weeks 0-24 Analysis Period Placebo/Standard of Care1/214 (0.5%)14/214 (6.5%)39/214 (18.2%)
Weeks 0-52 Analysis Period Baxdrostat1/192 (0.5%)23/192 (12%)83/192 (43.2%)
Weeks 0-52 Analysis Period Placebo/Standard of Care1/123 (0.8%)9/123 (7.3%)25/123 (20.3%)
Weeks 13-52 Analysis Period Baxdrostat 2mg0/127 (0%)6/127 (4.7%)44/127 (34.6%)
Weeks 13-52 Analysis Period Standard of Care0/49 (0%)2/49 (4.1%)12/49 (24.5%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboWeeks 0-24 Analysis Period BaxdrostatWeeks 0-24 Analysis Period Placebo/Standard of CareWeeks 0-52 Analysis Period BaxdrostatWeeks 0-52 Analysis Period Placebo/Standard of CareWeeks 13-52 Analysis Period Baxdrostat 2mgWeeks 13-52 Analysis Period Standard of Care
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2640/2660/2640/1720/850/4810/2141/1920/1230/1271/49
Cerebral artery embolismNervous system disorders0/2640/2660/2640/1720/850/4810/2140/1920/1230/1271/49
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2640/2660/2640/1720/850/4810/2140/1920/1230/1271/49
Cardiac failureCardiac disorders0/2640/2660/2640/1720/850/4812/2140/1922/1230/1270/49
Angina pectorisCardiac disorders0/2640/2660/2640/1720/852/4810/2142/1920/1230/1270/49
Small intestinal obstructionGastrointestinal disorders0/2641/2660/2640/1720/852/4810/2142/1920/1230/1270/49
HaemorrhoidsGastrointestinal disorders0/2640/2661/2640/1720/850/4812/2140/1921/1230/1270/49
Septic shockInfections and infestations0/2640/2662/2640/1720/850/4812/2140/1921/1230/1270/49
HypervolaemiaMetabolism and nutrition disorders0/2640/2662/2640/1720/850/4812/2140/1921/1230/1270/49
Acute myocardial infarctionCardiac disorders0/2640/2660/2640/1720/851/4811/2140/1921/1231/1270/49
Most frequent other events
Most frequent other events
EventDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboRandomised Withdrawal Period Weeks 25-32 Baxdrostat 2mgRandomised Withdrawal Period Weeks 25-32 PlaceboWeeks 0-24 Analysis Period BaxdrostatWeeks 0-24 Analysis Period Placebo/Standard of CareWeeks 0-52 Analysis Period BaxdrostatWeeks 0-52 Analysis Period Placebo/Standard of CareWeeks 13-52 Analysis Period Baxdrostat 2mgWeeks 13-52 Analysis Period Standard of Care
HyperkalaemiaMetabolism and nutrition disorders16/26431/2667/26417/1724/8569/4667/20847/734/4720/623/29
HyponatraemiaMetabolism and nutrition disorders3/26410/2662/2646/1722/8520/4661/20811/731/4711/621/29
Upper respiratory tract infectionInfections and infestations7/2641/26610/2641/1721/858/48111/2147/1926/1233/1274/49
HypertensionVascular disorders5/2644/2669/2640/1721/8511/48110/2145/1926/1233/1274/49
HypotensionVascular disorders6/26410/2662/2640/1720/8518/4812/21413/1924/1237/1270/49
NasopharyngitisInfections and infestations8/2648/2666/2643/1721/8523/4817/21411/1925/1235/1271/49
ArthralgiaMusculoskeletal and connective tissue disorders1/2646/2662/2641/1720/858/4812/21410/1921/1232/1270/49
DizzinessNervous system disorders7/2649/2664/2641/1721/8524/4814/21410/1923/1235/1270/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboTotal
Mean59.8 ± 11.861.8 ± 11.761.9 ± 11.661.1 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboTotal
Female95103102300
Male169163162494
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboTotal
Race : American Indian or Alaska Native0000
Race : Asian657272209
Race : Black or African American23211559
Race : Native Hawaiian or Other Pacific Islander1012
Race : White165168167500
Race : Multiple1102
Race : Other81716
Race : Missing1326
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboTotal
Ethnicity : Hispanic or Latino273938104
Ethnicity : Not Hispanic or Latino231216216663
Ethnicity : Missing6111027
Seated Systolic Blood Pressure
Seated Systolic Blood Pressure(mmHg)Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mgDouble-Blind Treatment Period Weeks 0-12 Baxdrostat 2mgDouble-Blind Treatment Period Weeks 0-12 PlaceboTotal
Mean149.7 ± 10.1149.1 ± 9.1149.0 ± 8.7149.3 ± 9.3
08

Study locations

263 sites
  • Research Site
    Saraland, Alabama 36571, United States
  • Research Site
    Scottsdale, Arizona 85054, United States
  • Research Site
    Sun City West, Arizona 85375, United States
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Little Rock, Arkansas 72211, United States
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Lincoln, California 95648, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Rancho Cucamonga, California 91730, United States
  • Research Site
    Stanford, California 94304, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    East Point, Georgia 30344, United States
  • Research Site
    Springfield, Illinois 62702, United States
  • Research Site
    Munster, Indiana 46321, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Olive Branch, Mississippi 38654, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Kansas City, Missouri 64128, United States
  • Research Site
    Kansas City, Missouri 64151, United States
  • Research Site
    Rosedale, New York 11422, United States
  • Research Site
    The Bronx, New York 10455, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Toledo, Ohio 43614, United States
  • Research Site
    Grants Pass, Oregon 97527, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Langhorne, Pennsylvania 19047, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Memphis, Tennessee 38105, United States
  • Research Site
    Brownsville, Texas 78526, United States
  • Research Site
    Corpus Christi, Texas 78404, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    Manassas, Virginia 20110, United States
  • Research Site
    Suffolk, Virginia 23435, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Milwaukee, Wisconsin 53295, United States
  • Research Site
    CABA, C1119ACN, Argentina
  • Research Site
    CABA, C1425HFA, Argentina
  • Research Site
    Ciudad de Buenos Aires, AR-CP 1221, Argentina
  • Research Site
    Córdoba, 5000, Argentina
  • Research Site
    Córdoba, X5003DCP, Argentina
  • Research Site
    Mar del Plata, B7600, Argentina
  • Research Site
    Mendoza, M5500, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    San Nicolás, B2900DMH, Argentina
  • Research Site
    San Vicente, 5006, Argentina
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Epping, 3076, Australia
  • Research Site
    Geelong, 3220, Australia
  • Research Site
    Liverpool, 2170, Australia
  • Research Site
    New Lambton Heights, 2305, Australia
  • Research Site
    Perth, 6000, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Braunau am Inn, 5280, Austria
  • Research Site
    Sankt Pölten, 3100, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Mons, 7000, Belgium
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Sofia, 1680, Bulgaria
  • Research Site
    Sofia, 1709, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 2C8, Canada
  • Research Site
    North Vancouver, British Columbia V7M 2H4, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Markham, Ontario L3S 0A2, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P6, Canada
  • Research Site
    Ottawa, Ontario K1H 7W9, Canada
  • Research Site
    Scarborough Village, Ontario M1B 4Z8, Canada
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
  • Research Site
    Waterloo, Ontario N2T 0C1, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Saint-Jean-sur-Richelieu, Quebec J3A 1J2, Canada
  • Research Site
    Benešov, 256 01, Czechia
  • Research Site
    Brandýs nad Labem, 250 01, Czechia
  • Research Site
    Broumov, 55001, Czechia
  • Research Site
    Louny, 440 01, Czechia
  • Research Site
    Ostrava, 708 52, Czechia
  • Research Site
    Příbram, 261 01, Czechia
  • Research Site
    Uherské Hradiště, 68601, Czechia
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Herning, 7400, Denmark
  • Research Site
    Holbæk, 4300, Denmark
  • Research Site
    Bobigny, 93000, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Saint-Priest-en-Jarez, 42270, France

Showing the first 100 of 263 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderang U, Wittes J, Williams B; BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025 Oct 9;393(14):1363-1374. doi: 10.1056/NEJMoa2507109. Epub 2025 Aug 30. PubMed 40888730 ↗
  • Flack JM, Azizi M, Brown JM, Dwyer JP, Jones ESW, Lihn AS, Liu L, Olsson DS, Perl S, Shibata H, Wang JG, Wilderang U, Wittes JT, Williams B. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025 Nov;48(11):2911-2923. doi: 10.1038/s41440-025-02297-7. Epub 2025 Aug 25. PubMed 40850955 ↗
  • Schiffrin EL. New Kids on the Hypertension Block: Novel Agents With New Mechanisms of Action. Am J Hypertens. 2024 Aug 14;37(9):651-653. doi: 10.1093/ajh/hpae051. No abstract available. PubMed 39138914 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in May 2025, 17 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is close to that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 13, 2023
StartActual
Nov 22, 2023
Primary completionActual
May 21, 2025
CompletionActual
Oct 10, 2025
Results first posted
Jul 30, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 3, 2026
Sites
1 site added, 1 site removed
Show site
  • Research Site · East Point, United States
Show 1 removed
  • Research Site · Atlanta, United States
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Posted results revised
    1 site added, 1 site removed
    Show site
    • Research Site · East Point, United States
    Show 1 removed
    • Research Site · Atlanta, United States
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06034743
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Nov 22, 2023
Primary completion
May 21, 2025
Completion
Oct 10, 2025
Results posted
Jul 30, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion